Exacerbations and Their Outcomes International (EXACOS International)
NCT ID: NCT05750810
Last Updated: 2023-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3477 participants
OBSERVATIONAL
2012-04-30
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease
NCT03450603
Exploring Clinical Predictors of COPD Exacerbation in a Community Cohort
NCT05762861
EXACOS EG Population
NCT06983340
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study
NCT02657525
Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
NCT02346292
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Studies have shown that AECOPDs are related to future AECOPDs, however, little is known about clinical burden and health care utilization in the COPD population \[2, 5\]. To date, most of published literature reports a combined category of moderate-severe exacerbations, typically stratifying patients as experiencing frequent (i.e. two or more events per patient-year) vs. infrequent (none or one) exacerbations.
The aim of this study is to quantify the burden of severe AECOPD in South Korea, by investigating the association between frequency of severe AECOPD and clinical and health-care utilization outcomes.
This study will help to understand the relationship between severe AECOPD and clinical and health care utilization burden in South Korea with no established health care databases.
2. OBJECTIVES AND HYPOTHESES The objective is to quantify the burden of severe AECOPD by describing the clinical and health care utilization burden of AECOPD by frequency.
2.1 Primary Objectives
2.1 Primary Objectives \& Hypothesises
1. To estimate the frequency of severe AECOPD, in a COPD population
2. To describe any time trends in the frequency of severe exacerbations throughout the study period (over a 2-year period)
3. To describe lung function decline over time (FEV1)
4. To quantify health care resource utilization by number of severe AECOPD over a 2-year period
2.2 Secondary Objective \& Hypothesis
1. Modified Medical Research Council (mMRC) dyspnea scale measured at time of the visit
3\. METHODOLOGY
3.1 Study Design - General Aspects This study was based on the Korea COPD Subgroup Study (KOCOSS) database, constructed from a nationwide prospective cohort study-initiated in April 2012-that involved 54 medical centers in South Korea.
During the patient visit, data was captured through the use of Case Report Forms (CRFs) by a doctor or trained nurse. After a baseline evaluation, patients were examined at 1-year follow-up.
3.2 Study Population
Inclusion criteria of the KOCOSS database is as follows:
1\) Age \> 40 years; 2) those with post-bronchodilator (FEV1)/forced vital capacity (FVC) ≤ 70% of the normal predicted value.
The following subpopulations of interest will be identified:
• Patients with eosinophils ≥100cells/ul
• Patients with a history of a comorbidity of special interest:
\- Any history of major cardiovascular comorbidity as recorded in the medical records: AMI, heart failure, stroke (+ MACE)
\- Any cardiovascular risk factor as recorded in the medical history: hypertension, diabetes - Any history of other major comorbidity: depression, anxiety, GERD, renal failure, etc.
3.3 Study Period Data of COPD patients from April 2012 to 2021 will be extracted and analyzed
4\. VARIABLES AND EPIDEMIOLOGICAL MEASUREMENTS
4.1 Exposures
The main exposure for this study is severe exacerbation frequency. A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms. The number of severe AECOPD was counted at the initial visit in recall of previous 1-year events, and prospectively measured at 1-year follow up visit. The annual severe AECOPD frequency will be estimated in the 2 years (pre- and post- 1-year of initial visit), and divided by 2. This will guide the categorization of the severe AECOPD frequency. We expect the following categories:
\- 0 events
\- 1 severe event
* 2 severe events
* 3 severe events
* \>3 severe events
The distribution of exacerbations across the entire 2 year period will also be described. In order to fully describe severe AECOPDs and their impact in disease progression, clinical burden, and healthcare costs the following outcomes will be measured:
1\) Clinical burden defined as change in lung function (FEV1) over time 2) Co-morbidities 3) Health care utilization burden will be defined accounting for:
-number of emergency department visits
-number of hospitalizations
-number of ICU episodes
5\. STATISTICAL ANALYSIS PLAN
5.1 Statistical Methods - General Aspects Summary statistics will be provided for the COPD population overall and by sub-populations noted above. Continuous measures will be described using means and standard deviations and categorical measures will be reported using numbers and proportions. Count variables will be expressed as rates per person-year. Groups will be compared using standard univariate statistical methods, including the chi-square test or the Fisher exact test for categorical variables and the analysis of variance test for continuous variables.
5.2 Sample Size and Power Calculations No power calculations were performed as the objectives of this study are mostly descriptive in nature.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Severe exacerbation frequency
A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. COPD patients who complain of cough, sputum, dyspnea
3. Unrelated smoking history
Exclusion Criteria
2. patients who is not suitable for pulmonary function test and communication
3. myocardial infarction or cerebrovascular event within the previous 3 months
4. pregnants
5. patients who disagree with registration
6. rheumatoid patients
7. cancer patients(including metastatic cancer, leukemia, lymphoma)
8. irritable bowel syndrome
9. patients who use systemic steroids over 8 weeks due to other diseases except COPD
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul St. Mary's Hospital
OTHER
Hallym University Medical Center
OTHER
Konkuk University Hospital
OTHER
Joon Young Choi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joon Young Choi
Clinical assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Incheon St. Mary's Hospital
Incheon, Gyeongki, South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rhee CK, Choi JY, Park YB, Yoo KH. Clinical Characteristics and Frequency of Chronic Obstructive Pulmonary Disease Exacerbations in Korean Patients: Findings From the KOCOSS Cohort 2012-2021. J Korean Med Sci. 2024 May 20;39(19):e164. doi: 10.3346/jkms.2024.39.e164.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESR-21-21659
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.